1 not yet recruiting, 1 recruiting, 1 terminated, 1 withdrawn. 4 Phase 1, 4 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 4 | Not yet recruiting 1, Recruiting 1, Terminated 1, Withdrawn 1 |
| Phase 2 | 4 | Not yet recruiting 1, Recruiting 1, Terminated 1, Withdrawn 1 |
Follow Toxic Epidermal Necrolysis: new trials by email Literature Review of Toxic Epidermal Necrolysis trials Research Report on Toxic Epidermal Necrolysis
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| New Therapeutic Target for Toxic Epidermal Necrolysis (TEN) Using Anti-CD38+ Monoclonal Antibodies. DARATUMUMAB (DARZALEX®) - Toxic Epidermal Necrolysis, Immunotherapy | Phase 1 / Phase 2 | Not yet recruiting | Hospices Civils de Lyon | 9 | 2025-10-29 | 2025-08-07 |
| LYell SYndrome MEsenchymal Stromal Cells Treatment Adipose derived stromal cells intravenously injected - Epidermal Necrolysis, Lyell Syndrome | Phase 1 / Phase 2 | Recruiting | Assistance Publique - Hôpitaux de Paris | 15 | 2024-04-15 | 2025-08-01 |
| Topical Clobetasol for the Treatment of Toxic Epidermal Necrolysis Clobetasol 0.05% ointment, Placebo - Toxic Epidermal Necrolysis | Phase 1 / Phase 2 | Withdrawn | University of California, Davis | 2016-11-01 | 2019-08-09 | |
| Study to Evaluate the Use of Palifermin to Treat Toxic Epidermal Necrolysis Palifermin - Toxic Epidermal Necrolysis, Stevens-Johnson Syndrome | Phase 1 / Phase 2 | Terminated | Brett King | 1 | 2010-10-01 | 2016-11-30 |
Chemically-Induced Disorders (4) · Dermatitis (4) · Drug Eruptions (4) · Drug Hypersensitivity (4) · Drug-Related Side Effects and Adverse Reactions (4) · Erythema (4) · Erythema Multiforme (4) · Hypersensitivity (4) · Hypersensitivity, Delayed (4) · Immune System Diseases (4) · Mouth Diseases (4) · Skin Diseases (4) · Skin Diseases, Vesiculobullous (4) · Skin and Connective Tissue Diseases (4) · Stomatitis (4)
Clobetasol (1) · Fibroblast Growth Factor 7 (1) · Ointments (1) · daratumumab (1)
Assistance Publique - Hôpitaux de Paris (1) · Brett King (1) · Hospices Civils de Lyon (1) · University of California, Davis (1)
France (2) · United States (2)
Emanual Maverakis, MD (1) · Saskia Oro, PhD (1)